Phase I open-label trial evaluating BI 1810631 as monotherapy in the treatment of patients with advanced or metastatic solid tumors with HER2 aberrations (BEAMION-Lung 1)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Her2 Mutation-positive Nsclc
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Histologically or cytologically confirmed diagnosis of an advanced, unresectable and/or metastatic non-haematologic malignancy
    2. Availability and patient willingness to provide a sample of tumour for confirmation of the patient´s HER2 status
    3. Life expectancy of at least 12 weeks at the start of treatment

You may not be eligible for this study if the following are true:

    1. Major surgery performed within 4 weeks prior to first trial treatment or planned within 6 months after screening
    2. Treatment with a systemic anti-cancer therapy or investigational drug within 21 days of the first treatment
    3. Previous treatment with any TKI targeting HER2



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.